全文获取类型
收费全文 | 3749篇 |
免费 | 288篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 117篇 |
妇产科学 | 119篇 |
基础医学 | 363篇 |
口腔科学 | 75篇 |
临床医学 | 431篇 |
内科学 | 762篇 |
皮肤病学 | 157篇 |
神经病学 | 163篇 |
特种医学 | 379篇 |
外国民族医学 | 1篇 |
外科学 | 478篇 |
综合类 | 244篇 |
一般理论 | 2篇 |
预防医学 | 382篇 |
眼科学 | 49篇 |
药学 | 145篇 |
中国医学 | 6篇 |
肿瘤学 | 139篇 |
出版年
2021年 | 37篇 |
2018年 | 44篇 |
2017年 | 30篇 |
2016年 | 39篇 |
2015年 | 47篇 |
2014年 | 71篇 |
2013年 | 108篇 |
2012年 | 103篇 |
2011年 | 125篇 |
2010年 | 116篇 |
2009年 | 104篇 |
2008年 | 123篇 |
2007年 | 112篇 |
2006年 | 108篇 |
2005年 | 107篇 |
2004年 | 112篇 |
2003年 | 105篇 |
2002年 | 102篇 |
2001年 | 83篇 |
2000年 | 92篇 |
1999年 | 99篇 |
1998年 | 79篇 |
1997年 | 75篇 |
1996年 | 82篇 |
1995年 | 74篇 |
1994年 | 64篇 |
1993年 | 64篇 |
1992年 | 106篇 |
1991年 | 102篇 |
1990年 | 102篇 |
1989年 | 128篇 |
1988年 | 115篇 |
1987年 | 94篇 |
1986年 | 112篇 |
1985年 | 105篇 |
1984年 | 79篇 |
1983年 | 51篇 |
1982年 | 55篇 |
1981年 | 30篇 |
1979年 | 38篇 |
1978年 | 36篇 |
1977年 | 41篇 |
1976年 | 49篇 |
1975年 | 52篇 |
1973年 | 41篇 |
1972年 | 46篇 |
1971年 | 39篇 |
1970年 | 29篇 |
1969年 | 30篇 |
1967年 | 35篇 |
排序方式: 共有4046条查询结果,搜索用时 15 毫秒
1.
P Tugwell L Hart G Kraag A Park C Dok F Bianchi C Goldsmith W W Buchanan 《The Journal of rheumatology》1984,11(4):457-461
A crossover double-blind controlled trial was performed on 36 patients with rheumatoid arthritis to assess the necessity for serum salicylate monitoring in determining optimal dosage. There was no clinically or statistically significant increase in the clinical improvement of patients associated with serum monitoring but potentially toxic serum levels occurred without tinnitus when serum monitoring was not used. 相似文献
2.
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
Michael Robson Isabelle Côte Ian Abbs Geoffrey Koffman David Goldsmith 《American journal of transplantation》2003,3(3):324-327
Thrombotic microangiopathy is a rare but important finding in the context of organ transplantation. Acute renal insufficiency in the setting of hemolysis and thrombocytopenia, a triad that constitutes 'hemolytic uremic syndrome', can be associated with, or triggered by, conditions such as verocytotoxin-producing Escherichia coli, viral infections, malignant hypertension, scleroderma, allograft rejection, lupus erythematosus, pregnancy, and medications including mitomycin C, calcineurin inhibitors, and oral contraceptives. After renal transplantation, it can occur, as either a de novo episode, or recurrent disease. Calcineurin inhibitors have long been associated with post-transplantation thrombotic microangiopathy. Sirolimus has been used as a primary immunosuppressant in patients transplanted with a history of earlier hemolytic-uremic syndrome, and also as rescue therapy in patients with calcineurin-inhibitor-associated thrombotic microangiopathy. We describe four cases where there was significant thrombotic microangiopathy in the context of contemporaneous or contiguous calcineurin inhibitor and sirolimus usage. As the intrarenal cyclosporin concentration is thought to be significantly elevated when cyclosporin and sirolimus are used together, this may explain these findings, and mandates caution in their co-administration. 相似文献
5.
6.
Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children 总被引:3,自引:3,他引:0
下载免费PDF全文
![点击此处可从《Antimicrobial agents and chemotherapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Brigitta U. Mueller Linda L. Lewis Geoffrey J. Yuen Maureen Farley Amy Keller Joseph A. Church Jonathan C. Goldsmith David J. Venzon Marc Rubin Philip A. Pizzo Frank M. Balis 《Antimicrobial agents and chemotherapy》1998,42(12):3187-3192
We studied the pharmacokinetics of intravenously and orally administered lamivudine at six dose levels ranging from 0.5 to 10 mg/kg of body weight in 52 children with human immunodeficiency virus infection. A two-compartment model with first-order elimination from the central compartment was simultaneously fitted to the serum drug concentration-time data obtained after intravenous and oral administration. The maximal concentration at the end of the 1-h intravenous infusion and the area under the concentration-time curve after oral and intravenous administration increased proportionally with the dose. The mean clearance of lamivudine (± standard deviation) in the children was 0.53 ± 0.19 liter/kg/h (229 ± 77 ml/min/m2 of body surface area), and the mean half-lives at the distribution and elimination phases were 0.23 ± 0.18 and 2.2 ± 2.1 h, respectively. Clearance was age dependent when normalized to body weight but age independent when normalized to body surface area. Lamivudine was rapidly absorbed after oral administration, and 66% ± 25% of the oral dose was absorbed. Serum lamivudine concentrations were maintained above 1 μM for ≥8 h of 24 h on the twice daily oral dosing schedule with doses of ≥2 mg/kg. The cerebrospinal fluid drug concentration measured 2 to 4 h after the dose was 12% (range, 0 to 46%) of the simultaneously measured serum drug concentration. A limited-sampling strategy was developed to estimate the area under the concentration-time curve for concentrations in serum at 2 and 6 h. 相似文献
7.
8.
N. J. Cortes B. Afzali D. MacLean D. J. A. Goldsmith H. O'Sullivan J. Bingham D. A. Lewis E. MacMahon C. Y. W. Tong G. Koffman 《American journal of transplantation》2006,6(10):2497-2499
Two organ recipients developed serologic evidence of syphilis infection after renal transplantation from a common deceased donor with a history of treated syphilis. Testing of donor serum for syphilis, which occurred after transplantation, gave results interpreted as consistent with past infection. However, subsequent serologic results in the recipients suggested transmission of infection at transplantation due to active infection of the donor. This may be explained by recent donor re-infection in view of the current syphilis epidemic in the United Kingdom. An initial error in the treatment of recipients further served to highlight unfamiliarity in managing this resurgent infection in the context of organ transplantation. 相似文献
9.